v3.26.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses    
Research and development expenses $ 2,405 $ 9,511
General and administrative expenses 8,672 7,168
Loss from operating activities (11,077) (16,679)
Foreign exchange loss (1) (17)
Change in fair value of derivative warrant liabilities 900 3,218
Interest and other income, net 685 711
Total other income, net 1,584 3,912
Loss before income tax benefit (9,493) (12,767)
Income tax benefit 1,700 3,199
Net loss (7,793) (9,568)
Total comprehensive loss $ (7,793) $ (9,568)
Basic loss per share (in Dollars per share) $ (0.47) $ (0.79)
Diluted loss per share (in Dollars per share) $ (0.47) $ (0.79)
Weighted average number of shares outstanding, basic (in Shares) 16,510,632 12,087,270
Weighted average number of shares outstanding, diluted (in Shares) 16,510,632 12,087,270